Working document · updated as we go

Our ME/CFS Research Log

A running, evidence-graded review of what's actually been studied on ME/CFS causes and treatments — built because "have you tried googling it" is not a referral pathway. Every entry below is graded by source quality, not vibes.

24 of 24 categories reviewed — full sweep complete 239 sources logged 7 promising leads, 4 ruled out Last updated 30 Jul 2026

What we know so far

The clearest verdicts — good or bad

All 24 categories are now reviewed. Seven things have cleared the bar for genuinely decent evidence, and four have been ruled out clearly enough that they're worth knowing even if you never look at the rest. Everything else is real but inconclusive — see the full board below.

Infection can genuinely trigger this

Promising

A large NIH-funded study (RECOVER-Adult, 2025) tracked 11,785 people infected with SARS-CoV-2 against 1,439 uninfected people. The infected group was roughly five times more likely to go on to develop ME/CFS. Earlier studies going back to 2006 show the same pattern with other infections (glandular fever, Ross River virus) — the people who got sickest during the initial infection were the ones most likely to develop lasting illness afterward.

This doesn't explain every case — plenty of people develop ME/CFS with no clear preceding infection — but it's the single best-evidenced trigger found in this research so far.

Why it matters: this is a measurable, replicated, physiological response to infection, tracked in large controlled studies. Not a mystery, not "in your head."

12 sources reviewed · see sources.csv, category "Post-viral/post-infectious onset"

Pacing is the one thing every guideline agrees on

Promising

NICE (UK) and the CDC (US) both recommend staying inside a personal "energy envelope" — tracking what you can actually do without triggering a crash, and not exceeding it — over any fixed, incrementally-increasing exercise program. In 2021, NICE formally reversed its older guidance and now explicitly warns against Graded Exercise Therapy (GET), the "push through it, build up slowly" approach.

A 2019 patient survey of 2,310 people found roughly 45% reported improvement from pacing, versus roughly 10% from GET or CBT-based approaches — that survey was part of the evidence that led to NICE's reversal.

Why it matters: if a GP, an old leaflet, or a well-meaning relative suggests "just build up your exercise," that guidance has been formally withdrawn by NICE. It's not a lack of willpower — pushing through can make things worse.

12 sources reviewed · see sources.csv, category "Pacing / energy envelope management"

Structured exercise programs (GET) have been withdrawn as advice

Ruled out

Graded Exercise Therapy — fixed, incrementally-increasing exercise — used to be standard advice, built on a 2011 trial (PACE) that claimed strong recovery rates. An independent 2018 reanalysis of that trial's own data, using its original pre-registered scoring rules instead of the loosened ones actually published, found "recovery" rates fell from a claimed 60% to just 20%, and the difference from doing nothing stopped being statistically real.

Both NICE and the CDC have formally withdrawn GET as a recommendation. A large UK patient survey found 74% of people who tried it said it made them worse.

Why it matters: this is the single most actionable finding in this research so far. If anyone suggests a fixed, build-up exercise program as a treatment, the evidence it was based on didn't hold up, and the guidance has been officially reversed since 2021.

10 sources reviewed · see sources.csv, category "Graded Exercise Therapy (GET)"

Mast cell issues show up often enough to be worth checking

Promising

Mast Cell Activation Syndrome (MCAS) — where immune cells release excess histamine and other mediators — turned up in roughly 17–25% of ME/CFS patients across the largest study found (over 1,000 people combined). People with both conditions had noticeably more orthostatic intolerance (standing-up problems), and responded significantly better to mast-cell-targeted treatment than those without it.

This is genuinely early-stage: no randomized trials exist yet, and even a leading ME/CFS clinic (Bateman Horne Center) says plainly there's "no robust research to confirm a link" despite seeing it constantly in practice.

Why it matters: if certain symptoms (flushing, hives, reactions to heat/food/fragrance) are part of the picture, it may be worth asking a GP about MCAS specifically — not as a proven fix, but as a genuinely plausible, testable comorbidity.

9 sources reviewed · see sources.csv, category "Mast cell activation syndrome (comorbid)"

"It's not in your head" isn't just reassurance — it's the evidence

Ruled out

For decades, some UK psychiatric medicine framed ME/CFS as perpetuated by "false illness beliefs" — the theory that justified CBT/GET as a cure. Both NICE and the 2015 Institute of Medicine report formally rejected this after reviewing the evidence. The most direct test came from a huge Dutch population study (Lifelines, ~136,000 people): among people with no prior fatigue, having a pre-existing psychiatric diagnosis did not predict who went on to develop ME/CFS.

This doesn't mean mental health is irrelevant — living with any severe chronic illness genuinely causes real rates of depression and anxiety, and that's worth taking seriously and treating. But that's a consequence of being sick, not the cause of it, and conflating the two is exactly the mistake this field made for years.

Why it matters: around 90% of ME/CFS patients report being told at some point their symptoms were psychosomatic before diagnosis. That framing has been formally withdrawn by the bodies that once endorsed it.

9 sources reviewed · see sources.csv, category "Psychological/psychiatric factors"

Brain fog and pain amplification may have a real inflammatory basis

Promising

Several different research methods — brain scans, spinal fluid analysis, imaging that detects immune cell activation — all point the same direction: something measurably different is happening in the brain and spinal cord of ME/CFS patients, concentrated in areas that handle pain, cognition, and emotion. A 2024 pooled analysis of 65 studies (over 3,200 people) found this most consistently in the thalamus and insula.

Genuinely early-stage though: the single most famous study in this area (finding activated immune cells in the brain via PET scan) failed to replicate when an independent team tried the same test again. Two major research charities are funding bigger studies specifically to settle this.

Why it matters: gives a plausible physical basis for brain fog and amplified pain, on top of everything else already found — another data point against "it's psychological."

11 sources reviewed · see sources.csv, category "Neuroinflammation / CNS sensitization"

Antihistamines may help — especially alongside MCAS

Promising

Following on from the mast cell finding above: the two ME/CFS-specific data points both point the same way — a small trial of high-dose cromolyn sodium (a mast cell stabilizer) helped patients who hadn't responded to standard dosing, and the larger MCAS comorbidity study found people responded significantly better to mast-cell-targeted treatment.

Most of the supporting evidence beyond that is borrowed from adjacent conditions (general MCAS, Long COVID) rather than ME/CFS trials specifically, and neither NICE nor the CDC endorse this as standard treatment yet — it's what specialist ME/CFS clinicians are doing in practice, not yet formal guidance.

Why it matters: low-cost, generally low-risk, and worth raising with a doctor if MCAS-type symptoms (flushing, hives, reactions to heat/food/fragrance) are part of the picture — genuinely worth trying, not yet proven at scale.

7 new sources reviewed · see sources.csv, category "Antihistamines/mast cell stabilizers"

Rituximab looked like a breakthrough, then wasn't

Ruled out

Rituximab (a drug that depletes a type of immune cell) produced a dramatic result in a small 2011 trial — 67% of treated patients improved versus 13% on placebo — and a 2015 follow-up reported 64% improvement. This generated years of patient and researcher excitement.

The definitive, much larger trial (151 people, published 2019) found the opposite: 26% improved on rituximab versus 35% on placebo — numerically worse, and not a real statistical difference — with more side effects in the treatment group. NICE now explicitly advises against it.

Why it matters: a textbook case of why early, small, unblinded results shouldn't be chased before the definitive trial reports. If rituximab ever comes up as an option, the answer is no, on current evidence — this isn't a treatment worth pursuing or paying for.

9 sources reviewed · see sources.csv, category "Immunomodulatory therapy"

There's a real, modest genetic component

Promising

Twin studies, family-clustering data, and a large 2025 UK genetic study (DecodeME) all point the same way: some people are genuinely more genetically susceptible to developing ME/CFS, usually after an infection or other trigger. DecodeME found 8 specific gene regions linked to immune response and chronic pain.

The genetic effect is real but modest — it explains roughly 10% of the picture, not most of it, and the DecodeME study is still a preprint (not yet formally peer-reviewed). This isn't a story of "it's just genetic" — it's one piece alongside the infection trigger and immune response already covered above.

Why it matters: reinforces, again, that this is a real biological condition with a measurable genetic signature — not a diagnosis of exclusion or a psychological label.

9 sources reviewed · see sources.csv, category "Genetic/epigenetic predisposition"

Nerve damage may explain some of the pain and standing-up problems

Promising

Three separate studies, using three different objective tests (a skin biopsy that counts nerve endings, a test that measures skin's electrical response, and a scan of the surface of the eye), all found the same thing: roughly a third of ME/CFS patients have measurable damage to their small nerve fibers — the ones that handle pain signaling and automatic body functions like sweating and blood vessel control.

This plausibly connects to two things already covered: the orthostatic intolerance/POTS findings above, and unexplained pain. No large study or guideline body has weighed in yet, so treat this as a real, replicated, but still emerging lead.

Why it matters: if pain or standing-related symptoms are prominent, this is a genuinely testable, objective finding (via a simple skin biopsy) worth raising with a neurologist — not just something to describe and hope is believed.

9 sources reviewed · see sources.csv, category "Small fiber neuropathy"

Restrictive diets don't help — and can actively hurt

Ruled out

Elimination diets, gluten-free, dairy-free, low-sugar/low-yeast — two systematic reviews and a dedicated trial all found no benefit over just eating a normal, balanced diet. Neither NICE nor the CDC recommend any specific restrictive diet, and patient charities actively warn against them.

This matters because restrictive eating carries real risk of malnutrition, especially for someone more severely affected who already struggles with meal prep and energy for cooking. There's a small amount of promise for a Mediterranean-style diet, but even that trial only measured whether people stuck to it, not whether it helped symptoms.

Why it matters: if a wellness forum or well-meaning suggestion pushes an elaborate elimination protocol, the evidence doesn't back it, and the added restriction/effort may do more harm than good. A normal, balanced diet is the evidence-backed choice.

8 sources reviewed · see sources.csv, category "Dietary interventions"

Full status board

Every category we're tracking

Click a row to expand our working notes. Source counts and confidence grow as we work through the list — nothing here is final.

Possible Causes

Post-viral / post-infectious onset 12 sources Promising ▸
Best-evidenced trigger found so far — large matched-control studies (COVID and earlier viruses) consistently show a dose-related minority developing ME/CFS after infection, tied to how severe the initial illness was. Explains a subset of cases, not all of them; what happens biologically after the trigger is still unclear (immune dysregulation is the leading candidate).
Immune dysregulation / chronic immune activation 14 sources Inconclusive ▸
Reduced natural killer (NK) cell activity is well-replicated across multiple independent reviews — one of the more solid objective findings in the field. But general inflammation markers (cytokines) are inconsistent study to study, and the largest single study found cytokines track with how severe someone's illness is, not whether they have it at all. Autoimmune-antibody findings are real but only show up in a subset (roughly a quarter) of patients.
Autonomic nervous system dysfunction (POTS, orthostatic intolerance) 10 sources Inconclusive ▸
Genuinely common and clinically significant — heart rate, blood pressure, and even blood flow to the brain on standing are frequently abnormal. But the best-powered study comparing ME/CFS patients to other fatigued patients found no meaningful difference in how common POTS was between the two groups — suggesting this may be a common companion condition rather than a distinguishing cause. Testing methods also vary a lot between studies.
Mitochondrial / metabolic dysfunction 12 sources Inconclusive ▸
The body's response to exertion is measurably and reproducibly abnormal — this is essentially the physical signature of post-exertional malaise. But whether that's caused by broken mitochondria specifically, or something further upstream (like oxygen delivery), is unresolved. One well-designed study found normal mitochondrial function in cells despite clearly abnormal real-world exercise performance in the same patients.
Neuroinflammation / CNS sensitization 11 sources Promising ▸
See the featured write-up above. Multiple methods (PET imaging, spinal fluid analysis, MR spectroscopy, a 2024 meta-analysis of 65 studies) converge on real CNS-level abnormality, concentrated in regions handling pain/cognition/emotion. Held back from a stronger verdict because the field's flagship single-study finding failed an independent replication attempt, and every case-control study is small. Active area of major research charity funding.
HPA axis dysfunction (cortisol/stress response) 10 sources Inconclusive ▸
The signal itself is real and well-replicated — mild low cortisol, blunted daily cortisol rhythm, and an exaggerated shutdown response, going back to a 1991 foundational study through a 2026 meta-analysis. It's biologically distinct from the high cortisol seen in classic depression. But the causal test undercuts it: replacing the missing cortisol with hydrocortisone only produced modest, short-term improvement in one trial, and in another, a higher dose caused clinically significant adrenal suppression severe enough the authors ruled out practical use. Most likely a downstream marker, not a fixable root cause.
Gut microbiome / gastrointestinal dysfunction 12 sources Inconclusive ▸
A real, active research thread — the largest study (233 people) consistently found reduced gut bacterial diversity and leaky-gut markers in ME/CFS patients. But the only formal review of all the studies found the results too inconsistent to call this a driver rather than a downstream effect, and no guideline body discusses it as a cause. A trial testing fecal transplants directly is underway but hasn't reported results yet.
Genetic / epigenetic predisposition 9 sources Promising ▸
See the featured write-up above. Twin studies, family clustering, and a large 2025 UK genetic study (DecodeME, still a preprint) converge on a real but modest genetic contribution (~10% of the picture), consistent with the model both NICE and CDC already describe: genetic susceptibility plus an environmental trigger.
Small fiber neuropathy 9 sources Promising ▸
See the featured write-up above. Three independent studies using three different objective test methods all found roughly 30-34% of ME/CFS patients have measurable small-nerve-fiber damage, plausibly linked to pain and standing-related symptoms. No dedicated large review exists yet and no guideline body has weighed in, but the cross-method consistency is notable.
Mast cell activation syndrome (comorbid) 9 sources Promising ▸
Early-stage but a genuine signal: the largest dataset found (n=687 + n=383) shows 17–25% comorbid prevalence, strongly linked to orthostatic intolerance, with a highly significant treatment-response difference favoring mast-cell-targeted therapy. Tempered by: no randomized trials exist yet, neither NICE nor the 2015 IOM report engages with MCAS at all, and the field's own diagnostic gold standard (a blood test called tryptase) is stricter than what most of these studies actually used. Plausible and patient-embraced, not yet formally proven.
Sleep architecture abnormalities 9 sources Inconclusive ▸
Objective sleep-study differences do exist on average (less efficient sleep, longer time to fall asleep, more awakenings) but are inconsistent study to study and, tellingly, don't track with how bad someone's "unrefreshing sleep" complaint actually is — an odd disconnect. The 2015 IOM report was explicit that standard sleep studies usually look basically normal despite the complaint being near-universal. One practical note: a study of patients referred for suspected ME/CFS found about 40% actually had obstructive sleep apnea on testing — worth ruling out a separate, treatable sleep disorder before assuming it's just "part of the illness."
Psychological / psychiatric factors 9 sources Ruled out ▸
See the featured write-up above — ruled out specifically as a primary cause of the illness, not as a claim that mental health doesn't matter once you're sick. NICE and the IOM both formally rejected the older "false illness belief" model; the strongest direct test (a ~136,000-person Dutch cohort) found pre-existing psychiatric diagnosis didn't predict who went on to develop ME/CFS. Secondary depression/anxiety from living with a severe chronic illness is real and well-documented — that's a consequence, kept clearly separate here from cause.

Possible Treatments

Pacing / energy envelope management 12 sources Promising ▸
Unanimously endorsed by NICE, the CDC, and the 2015 IOM report as safer and more appropriate than structured exercise. Meta-analyses show a moderate, consistent reduction in fatigue, and one 2025 review found pacing's benefits held up at 2.5-year follow-up where GET's did not. Caveat: no large multi-site trial exists yet, and in one survey around 14% of patients said pacing made things worse for them — individual variation matters.
Graded Exercise Therapy (GET) 10 sources Ruled out ▸
Ruled out as a recommended standard treatment — not a flat "never helps under any protocol." Both NICE (2021) and the CDC (2017) now advise against fixed-incremental exercise programs. The flagship 2011 trial that justified GET (PACE) was substantially undermined by an independent 2018 reanalysis using its own pre-registered scoring: claimed 60% recovery fell to 20% and lost statistical significance. A large patient survey found 74% who tried GET said it made them worse. A Cochrane review still says exercise therapy probably helps, but that review is itself under open dispute within Cochrane for being outdated.
CBT 10 sources Inconclusive ▸
Splits by framing. As coping support for living with a chronic illness: plausible and low-controversy, recent large meta-analyses show real, modest benefit. As treatment for the underlying disease (the historically contested claim, built on the same PACE trial as GET, above): doesn't hold up — the same independent reanalysis found CBT's claimed recovery rates collapsed under the original scoring rules. NICE and the CDC have both formally withdrawn CBT's status as a cure. Nearly every study on both sides relies on self-reported outcomes rather than objective measures.
Low-dose naltrexone (LDN) 8 sources Inconclusive ▸
Evidence doesn't yet back the patient-community buzz. NICE explicitly declined to recommend it in 2021 for lack of placebo-controlled trials — and that gap still hasn't been filled: only a small uncontrolled retrospective study (n=218, no placebo arm, ~74% reported a positive response) exists for ME/CFS specifically. Stronger results exist for related conditions (fibromyalgia, Long COVID) but aren't ME/CFS-specific. A large patient survey rated LDN the single most effective treatment tried — worth discussing with a doctor given its low cost and risk, but not yet clinically proven. Two real trials are underway.
Antiviral therapy 9 sources Inconclusive ▸
A consistent split: general ME/CFS populations show no benefit from antivirals (a 1988 placebo-controlled trial found nothing). But patients specifically selected for elevated EBV/HHV-6 antibody levels showed a possible, unconfirmed benefit in a small trial (30 people) — never independently replicated since, despite the same researchers calling for exactly that follow-up. NICE reviewed this in 2021, rated it very low quality, and doesn't recommend it. Bottom line: any positive signal applies to an antibody-tested minority, not everyone.
Supplements (CoQ10, D-ribose, carnitine, B vitamins, magnesium) 11 sources Inconclusive ▸
Not all supplements are equally evidenced. CoQ10 (especially paired with NADH or selenium) has the strongest case: the largest trial here (207 people) and the most recent systematic review both found real, statistically significant fatigue reduction. Magnesium, D-ribose, carnitine, and B12 each rest on only one or two small, old, or uncontrolled studies — meaningfully weaker evidence. Neither NICE nor two independent reviews recommend any supplement outright given the small sample sizes involved, but CoQ10 is the one worth an actual conversation with a doctor about.
POTS-directed treatment 9 sources Inconclusive ▸
Splits cleanly by type. Non-drug measures (salt/fluid loading, compression garments, careful posture changes) have the most consistent support and the lowest risk — one ME/CFS-specific trial found compression stockings measurably improved blood flow to the brain during standing tests. Medication is a mixed bag: beta-blockers and pyridostigmine both showed some benefit, but fludrocortisone — a mainstay for POTS generally — was tested head-to-head against placebo in ME/CFS patients specifically and failed outright. No guideline body recommends a specific drug order; both defer to specialist judgment.
Sleep management 8 sources Inconclusive ▸
Both NICE and the CDC recommend managing sleep as standard supportive care, but both openly admit the evidence for specific interventions is thin. Worth doing because it's low-risk and a core complaint, not because it's proven to improve ME/CFS overall. One practical note carried over from the causes side: screening for a separate, treatable sleep disorder (like sleep apnea) is worth ruling out first.
Antihistamines / mast cell stabilizers 7 sources Promising ▸
See the featured write-up above. Both ME/CFS-specific data points (a small cromolyn case series, and treatment-response data from the MCAS comorbidity study) point the same way. Most of the wider supporting evidence is borrowed from adjacent conditions rather than ME/CFS trials directly, and it's not yet guideline-endorsed — an emerging specialist practice, not proven at scale.
Immunomodulatory therapy (rituximab, IVIG) 9 sources Ruled out ▸
See the featured write-up above — rituximab is the clearest "promising pilot, failed definitive trial" story in this whole review (67% response in a small 2011 trial, then 26% vs 35% placebo in the real 151-person trial). NICE explicitly advises against it. IVIG has a thinner, older, mixed record and was never given a trial as rigorous as rituximab's — inconclusive rather than ruled out, but not a treatment to pursue on current evidence either.
Dietary interventions 8 sources Ruled out ▸
See the featured write-up above. Restrictive/elimination diets specifically show no benefit over normal balanced eating, and carry real malnutrition risk. General healthy eating remains sensible and is what both NICE and CDC actually recommend — this verdict is about elaborate restriction protocols, not food in general.
Emerging / repurposed drug trials 11 sources Inconclusive ▸
A genuine watch-list rather than evidence yet: low-dose aripiprazole, a novel stress-hormone-pathway drug (CT38), stellate ganglion block (a nerve-blocking procedure), and metformin all have some early signal, but every single one rests on small or uncontrolled trials, or data borrowed from Long COVID that hasn't been retested in ME/CFS yet. Stellate ganglion block has a proper follow-up trial underway right now — worth checking back on this category specifically in 6-12 months, it will likely look different.

What's next

First full sweep complete

All 24 originally-scoped categories have now been reviewed at least once. That doesn't mean the work is finished — research keeps publishing, a few sources here need manual verification (flagged in sources.csv), and some categories (gut microbiome, emerging drug trials, antihistamines) are moving fast enough to be worth revisiting in 6-12 months. This page will get a second pass rather than staying static.